GREGORY CORAM: Open Payments
NPI 1548373384 · TOMS RIVER, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$836 in 56 payments from 10 companies in 2025. Trend: 2023 $1,518 · 2024 $989 · 2025 $836
Food & beverage: $836
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $337 |
| Alkermes, Inc. | 5 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 4 | $66 |
| Janssen Pharmaceuticals, Inc | 3 | $55 |
| Neurocrine BioSciences, Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Almatica Pharma LLC | 2 | $35 |
| Braeburn Inc. | 1 | $16 |
Products named: VRAYLAR, REXULTI, ARISTADA, CAPLYTA, Auvelity, SPRAVATO, INGREZZA, LOREEV XR.
Industry payments across NJ — which companies pay providers there.
